Skip to main content

Table 3 The outcome of the neuropathological assessment

From: Cognitive function in very old men does not correlate to biomarkers of Alzheimer’s disease

Case #

Clinical diagnosis

Age

range

BW in grams

Braak HPτ stage

Thal Aβ phase

CAA type

Braak αS stage

pTDP43

Vascular pathology

PAD

NIA-AA

1

AD

86–90

1208

3

4

1

0

1

1

AD

intermediate

2

C

96–90

1317

1

1

1

0

0

0

ADRP

low

3

C

91–96

1261

3

4

0

0

1

0

ADRP

intermediate

4

C

91–96

1415

1

0

0

3

1

0

PART

none

5

C

91–96

1410

2

1

0

0

0

0

ADRP

low

6

C

91–96

1460

b

1

2

0

0

0

ADRP

low

7

C

91–96

1347

3

5

0

0

1

1

ADRP

intermediate

8

AD

91–96

1225

5

4

2

6

1

0

AD/ DLBD

high

9

C

91–96

1370

3

4

0

0

1

1

ADRP

intermediate

10

AD

91–96

1225

5

4

2

0

1

0

AD

high

11

C

91–96

1170

4

4

0

0

1

0

ADRP

intermediate

12

C

91–96

1315

1

3

1

0

1

1

ADRP

low

13

C

9–96

1300

4

3

2

0

1

1

ADRP

intermediate

  1. AD Alzheimer’s Disease, C cognitively unimpaired subject, BW brain weight, HPt, hyperphosphorylated tau, amyloid-β, CAA cerebral amyloid angiopathy, aS synuclein, pTDP43 phosphorylated transactive DNA binding protein, PAD PathoAnatomical Diagnosis, ADRP AD related pathology, DLBD Diffuse Lewy body disease, NIA-AA National Institute on Aging–Alzheimer’s Association